Overall survival in Cohorts 2 and 3 (full analysis set)
*Median follow up for OS was 9.4 months (PD-L1 ≥25%); 9.3 months (PD-L1 <25%); and 7.0 months (PD-L1 ≥90%)
NC, not calculated; NR, not reached
No. of patients at risk:
PD-L1 ≥25% 149
127
97
79
66
47
14
3
1
1
0
PD-L1 <25% 94
75
56
48
32
24
16
1
0
0
0
No. of patients at risk:
PD-L1 ≥90% 67
53
39
19
7
0
1.0
0
Proportion alive
0.8
0.6
0.4
0.2
0
3
6
9
30
12
15
18
21
24
27
1-year OS
47.7% (39.3–55.5)
34.5% (25.0–44.1)
1-year OS
50.8 (36.9–63.2)
Time from first dose (months)
1.0
0
Proportion alive
0.8
0.6
0.4
0.2
0
3
6
9
12
15
Time from first dose (months)
Cohort 2
Cohort 3
Median OS (95% CI)*
PD-L1 ≥90% (n=67):
NR (5.9–NC)
Median OS (95% CI)*
PD-L1 ≥25% (n=149):
10.9 (8.6–13.6)
PD-L1 <25% (n=94):
9.3 (5.9–10.8)
ATLANTIC (NCT02087423) is a Phase 2, open-label,
single-arm trial
